全球骨肉瘤市场 – 行业趋势和 2030 年预测

骨肉瘤市场分析和规模

民众意识的提高是推动市场增长的关键因素，此外，领先企业为推出更好的骨肉瘤治疗方法而增加研发活动、政府对研发的支持增加、对骨肉瘤等罕见癌症的新疗法的需求增加以及世界部分地区医疗保健支出的增加是推动对乙酰氨基酚 (Paracetamol) 市场增长的主要因素。此外，医疗设备技术进步和现代化的不断提高、医疗保健行业研发活动的不断增加以及老年人口基数不断增加的新兴市场的不断崛起将在预测期内为骨肉瘤市场创造新的机会。

Data Bridge Market Research 分析，骨肉瘤市场规模在 2022 年为 5.8414 亿美元，到 2030 年将飙升至 9.3734 亿美元，预计在预测期内的复合年增长率为 8.33%。这表明市场价值。由于技术进步的不断提高，“髓内骨肉瘤”在骨肉瘤市场类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

骨肉瘤市场范围和细分

Market Definition

Osteosarcoma or osteogenic sarcoma is the most common type of bone cancer, which develops in the cells that forms new bone tissues. Osteosarcoma most commonly occurs in the long bones of the body such as long bones of the hands or legs, although it can occur in any bone of the body. Symptoms of osteosarcoma include swelling and localized bone pain.

Global Osteosarcoma Market Dynamics

Drivers

• Increasing Incidence of Osteosarcoma

Osteosarcoma is one of the most common primary bone tumors, primarily affecting children and adolescents. The rising incidence of osteosarcoma globally is driving the demand for effective diagnosis, treatment, and management options

• Growing Focus on Precision Medicine

Precision medicine involves tailoring treatment strategies based on an individual's genetic profile, tumor characteristics, and overall health. The growing focus on precision medicine has led to the identification of specific genetic alterations and biomarkers in osteosarcoma, enabling targeted therapies and personalized treatment plans

• Innovations in Treatment Approaches

There have been significant advancements in the treatment of osteosarcoma, including surgical procedures, chemotherapy, targeted therapies, and radiation therapy. The development of novel treatment approaches, such as immunotherapy and personalized medicine, has shown promising results in improving survival rates and reducing treatment-related side effects

• Government Initiatives and Funding

Government initiatives aimed at improving cancer care, research funding, and healthcare infrastructure have contributed to the growth of the global osteosarcoma market. Increased funding allows for the development of new therapies, clinical trials, and the establishment of specialized centers for the diagnosis and treatment of osteosarcoma

Opportunities

• Rising Healthcare Expenditure

Increasing healthcare expenditure across the globe has positively impacted the osteosarcoma market. Higher healthcare spending allows for better infrastructure, improved access to healthcare services, and increased adoption of advanced treatment options, ultimately driving market growth

• Advancements in Diagnostic Technologies

Advances in diagnostic technologies, such as imaging techniques (X-ray, MRI, CT scans), molecular testing, and biopsy procedures, have improved the early detection and accurate diagnosis of osteosarcoma. These advancements have led to increased awareness, early intervention and improved patient outcomes

Restraints/Challenges

• High Cost of Treatment

The cost of osteosarcoma treatment can be substantial, including surgery, chemotherapy, radiation therapy, and supportive care. These expenses can place a significant financial burden on patients and their families. The high cost of treatment may limit access to advanced therapies and comprehensive care, particularly in low-income regions or countries with inadequate healthcare coverage

• Adverse Effects of Treatment

Osteosarcoma treatment, particularly chemotherapy and radiation therapy, can have significant side effects. These may include nausea, hair loss, fatigue, weakened immune system, and long-term complications such as organ damage. The potential for adverse effects can impact patient compliance with treatment regimens and quality of life

This osteosarcoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteosarcoma market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

• In December 2021, the Centers for Devices and Radiological Health of the FDA granted ZetaMet's breakthrough device for the treatment of metastatic bone cancers and osteological interventions
•  In October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc. acquisition to provide additional potential in various diseases, including infectious diseases and vaccines, neuroscience, oncology and pulmonary hypertension

Global Osteosarcoma Market Scope

The osteosarcoma market is segmented on the basis of type, diagnosis and treatment and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Intramedullary Osteosarcoma
• Juxtacortical Osteosarcoma
• Extraskeletal Osteosarcoma

Diagnosis and Treatment

• Treatment
• Diagnosis

End-User

• Hospitals and Clinics
• Diagnostic Centers
• Academic and Research Organizations

Osteosarcoma Market Regional Analysis/Insights

The osteosarcoma market is analysed and market size insights and trends are provided by country, type, diagnosis and treatment and end-user as referenced above.

The countries covered in the  osteosarcoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteosarcoma market because of the strong base of healthcare facilities, strong presence of major players in the market, increasing incidence of osteosarcoma and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period from 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Osteosarcoma Market Share Analysis

The osteosarcoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to osteosarcoma market.

Some of the major players operating in the osteosarcoma market are

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland.)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Bellicum Phamaceuticals, Inc (U.S.)
• Incyte (U.S.)
• Nektar Therapeutics（美国）
• Iovance Biotherapeutics（美国）
• Aurora 生物制药 (美国)
• BioAtla（美国）
• Acrotech Biopharma, Inc.（美国）
• Eleison Pharmaceuticals（美国）

SKU-60611